Mylan nabs exclusive Sovaldi, Harvoni deal in India; Bidvest bids $515M for full control of Adcock; Novo sees up to $335M from NNIT spinoff;


@FiercePharma: Brain cancer therapy pioneered in dogs wins NCI grant for human development. More | Follow @FiercePharma

@CarlyHFierce: Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash. Release | Follow @CarlyHFierce

> U.S.-based Mylan ($MYL) signed up with Gilead Sciences ($GILD) as its exclusive distributor for branded hepatitis C drugs Sovaldi and Harvoni in India; Mylan was already one of the drugmakers licensed to sell generic versions of the meds. Release

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

> South African conglomerate Bidvest has offered about $515 million to gain full control of drugmaker Adcock Ingram; it currently owns a 34.5% stake in the generics maker. Report

> Novo Nordisk ($NVO) says it expects to rake in up to 2.2 billion kroner ($335 million) in a public stock offering for 40% of its technology subsidiary, NNIT, at 100 to 120 kroner per share. Report

> Pfizer ($PFE) says the FDA accepted its application for a new use for Rapamune (sirolimus), its transplant drug, to treat a rare, often fatal lung disease, lymphangioleiomyomatosis. Release

> Japanese regulators slapped Gilead Sciences for failing to report side effects of three drugs awaiting approval in that country, but already on the market elsewhere. Report

Medical Device News

@FierceMedDev: J&J readies to rid itself of Cordis--for as much as $2B to Cardinal Health. More | Follow @FierceMedDev

@VarunSaxena2: Reg. standards may be for NGS materials, methods & performance. Specific for each area (oncology, germline mutations etc) #PrecisionMedicine. | Follow @VarunSaxena2

@EmilyWFierce: Bayer feels sting of mixed decision from NICE for Eylea's use in diabetics. Article | Follow @EmilyWFierce

> First adhesive varicose vein treatment wins FDA approval. More

> Advisory panel recommends FDA approval of VertiFlex's spinal implant. Story

Biotech News

@FierceBiotech: Merck KGaA carves into MS R&D after a string of setbacks. Story | Follow @FierceBiotech

@JohnCFierce: $LLY, that wunderkind of drug R&D, delays peglispro after all and Tim Anderson sounds taps. Release | Follow @JohnCFierce

@DamianFierce: Big day for Tularik expats, particularly the ones at Flexus and NGM. Story | Report | Follow @DamianFierce

> Celldex jumps after gaining an FDA 'breakthrough.' More

> Bristol-Myers bags IDO immunotherapy in $1.25B buyout of fledgling Flexus. Article

Biotech IT News

> AstraZeneca picks Labguru to improve collaborations with academia. More

> FDA puts cloud storage and Google-esque search tools on precision medicine road map. Story

> Big Data digging yields unprecedented road map of the epigenome. Article

> BGI investor: It is the database they are building that will make them formidable. Report

> Transcriptic snags $8.5M to add capabilities at robot-run lab. News

CRO News

> LabCorp seals its $6B deal for Covance. Article

> After a $300M IPO, PRA forecasts a big 2015. More

> Theorem partners up for patient testing. Report

> Parexel stretches out its site network to speed up enrollment. Story

> WuXi borrows $165M to bankroll more M&A. Item

Animal Health News

> Jaguar posts positive trial results on lead prescription drug for dogs. Item

> Patterson misses on sales and earnings but reaffirms fiscal 2015 guidance. Report

> Australia's Integrated Animal Health to open offices in U.S. Story

> Brain cancer therapy pioneered in dogs wins NCI grant for human development. News

> Dogs get pulled into the medical marijuana debate. Article

And Finally... The U.S. military's health plans spent $84 million on erectile dysfunction meds last year for its beneficiaries, including active-duty personnel, retirees and eligible family members. Report


Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.